ender diagnostics and SWISS collaborate to test cabin crew for COVID-19
ender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, today announced a collaboration with Swiss International Air Lines (SWISS), a subsidiary of Lufthansa AG, to test all long-haul cabin crew members for SARS-CoV-2, the virus which causes COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005019/en/
Swiss Airlines COVID-19 Test Center (Photo: Business Wire)
Constant rapid and flexible testing is the key to controlling the coronavirus pandemic. Testing SWISS long-haul crew members prior to departure working with ender diagnostics will help to further improve detection of COVID-19 infection, increasing the safety and confidence of people traveling.
Martin Knuchel, Head of Crisis, Emergency & Business Continuity Management Lufthansa Group Airlines and Pandemic Coordinator, commented: «The safety and confidence of our passengers and employees is paramount for SWISS. The decision to adopt the fast, innovative and easy-to-use testing solutions developed by ender diagnostics further underlines our absolute commitment to make air travel as safe as possible.»
ender diagnostics specializes in isothermal PCR*-based test kits for laboratory and on-site diagnosis. It has launched two CE-marked tests in Europe: ender LAB in June and ender MASS in August 2020. The ender LAB test allows laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes of extraction of the viral RNA. This is significantly faster than commercially available PCR tests, which take several hours. ender MASS offers additional benefits by enabling detection in a simplified process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, including travel-related locations such as airports and cruise ships.
Hans-Peter Frank, Chief Business Officer of ender diagnostics, said: «With simplified workflows and analysis, our products can process up to eight times as many tests as conventional PCR test over the same period. This significantly increases both test capacity and flexibility in laboratories and is a promising step towards mass screening. We are pleased to be able to support SWISS in their efforts to protect their passengers and employees.»
About ender diagnostics
ender diagnostics is a private company headquartered in Bern, Switzerland, and with US offices in Miami. ender diagnostics focuses on the development of rapid molecular tests for the detection of SARS-CoV-2. The ender team has extensive experience in developing molecular biological rapid tests for infectious diseases. The company is supported by several private investors with know-how and financing. https://enderdiagnostics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005019/en/
Contact information
For media inquiries, please contact:
media@enderdiagnostics.com
For more information about ender diagnostics’ products, please contact:
info@enderdiagnostics.com
Hans-Peter Frank
Chief Business Officer
hp.frank@enderdiagnostics.com
+41 79 743 27 77
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INNIO Secures Largest Order in Company History with VoltaGrid Delivering Power Generation for One of the World’s Largest Data Centers21.10.2025 10:01:00 EEST | Press release
INNIO Group today announced the largest order by power delivery in its history: a groundbreaking 2.3 GW power infrastructure project featuring 92 power packs, each delivering 25 MW of output. The initiative with VoltaGrid strengthens INNIO’s position as a key energy solutions provider for the rapidly expanding U.S. data center sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021503080/en/ INNIO Secures Largest Order in Company History (c) INNIO “This landmark order underscores the strength of INNIO’s technology and our ability to power the AI revolution with smart, high-performance energy solutions,” said Dr. Olaf Berlien, President and CEO of INNIO Group. “We are proud to partner with VoltaGrid in shaping the energy infrastructure of tomorrow.” “This is a major step toward building the energy infrastructure for the AI era,” added Nathan Ough, CEO of VoltaGrid. “Together with INNIO, we’re delivering a scalable solut
P.I. Works Celebrates 20 Years of Shaping the Telecom Industry21.10.2025 10:00:00 EEST | Press release
P.I. Works, the leading independent provider of AI-driven mobile network automation, optimization, and assurance solutions, proudly celebrates its 20th anniversary. This milestone marks two decades of driving telecom innovation and enabling mobile operators to deliver superior network performance, operational efficiency, and customer experience worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021105217/en/ P.I. Works Celebrates 20 Year Anniversary From Network Optimization to AI-Driven Automation Founded in 2005, as mobile data traffic surged with the rise of 3G, P.I. Works introduced intelligent solutions to help operators plan, manage, and optimize their networks more efficiently. Over the years, the company pioneered Self-Organizing Network (SON) capabilities, establishing the foundation for large-scale automation and giving operators the agility to manage increasingly complex networks. Leading Through the 5G
The Coca-Cola Company and Gutsche Family Investments Agree to Sell Controlling Interest in Coca-Cola Beverages Africa to Coca-Cola HBC AG21.10.2025 09:00:00 EEST | Press release
The Coca-Cola Company and Gutsche Family Investments have agreed to sell a 75% controlling interest in Coca-Cola Beverages Africa Pty. Ltd. to Coca-Cola HBC AG, the companies announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020939952/en/ CCBA is the largest Coca-Cola bottler in Africa. It operates in 14 countries on the continent and accounts for about 40% of all Coca-Cola product volume sold across Africa. Coca-Cola HBC is one of the largest Coca-Cola bottlers in the world, with operations in 29 countries across Europe and Africa, including Nigeria and Egypt. Coca-Cola will sell 41.52% out of its 66.52% stake in CCBA to Coca-Cola HBC, and Coca-Cola HBC is acquiring 33.48% of CCBA that is held by GFI. In total, the transaction values 100% of CCBA at an equity value of US$3.4 billion. The transactions are targeted to close by the end of 2026. Coca-Cola and Coca-Cola HBC have also agreed to a separate option
Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation21.10.2025 09:00:00 EEST | Press release
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/ Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscience. Scholars will also receive mentorship, professional development, and communication support to amplify the impact of their resear
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer21.10.2025 08:17:00 EEST | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, presented results from the Phase 1b dose escalation of the TheraPb Phase 1/2 clinical trial (NCT05720130) at the European Society for Medical Oncology (ESMO) 2025 congress. The presentation featured the first clinical results of 212Pb-ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy in mCRPC. “We are very encouraged by the completion of the treatment period of our Phase 1 trial, which has demonstrated a favorable safety profile and compelling anti-tumor activity for 212Pb-ADVC001," said Anna Karmann, MD PhD, Chief Medical Officer of AdvanCell. “These results underscore the potential of our therapy to meaningfully impact patients’ lives and advance treatment options in metastatic prostate cancer. I want to sincerely thank the investigators, clinical teams, and most importantly the patients and their families, whose commitment has made this important milestone pos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom